Kidney Cancer | Tumor

Promising Drug Puts Focus on Rare Condition That Can Lead to Growth of Tumors, Cysts

November 5th 2020, 7:00pm

Article

The FDA is reviewing what could become the first-ever medication specifically for kidney cancer associated with von Hippel-Lindau disease.

Can a Blood Test Detect Cancer in Asymptomatic Patients?

October 28th 2020, 3:00pm

Article

A liquid biopsy may soon be available to find early signs of cancer in asymptomatic patients when the disease is still treatable and even curable.

FDA Grants Priority Review to Opdivo-Cabometyx Combo for Advanced Kidney Cancer

October 27th 2020, 6:00pm

Article

The FDA granted a priority review to the biologics license application and new drug application for the combination of Opdivo and Cabometyx for patients with advanced kidney cancer.

Cabometyx-Tecentriq Combo Shows Promise in Advanced Kidney Cancer

October 5th 2020, 3:00pm

Article

“The combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) demonstrated encouraging clinical activity in previously untreated patients with advanced ccRCC,” Dr. Sumanta Kumar Pal, co-director of the Kidney Cancer Program at City of Hope in California, said during a presentation of the clear cell renal cell carcinoma cohort.

Surgery After Targeted or Immune Therapy Improves Health Outcomes in Some Patients with Metastatic Kidney Cancer

October 1st 2020, 1:00pm

Article

For some patients with metastatic kidney cancer, undergoing surgery after targeted or immune therapy sparks better health outcomes.

Data Sharing, Vigilance Pivotal in Maintaining Patient Safety While Treating Cancer Amid the COVID-19 Pandemic

September 2nd 2020, 3:00pm

Article

As the COVID-19 pandemic continues to impact the care of patients with metastatic renal cell carcinoma and other cancers, health care professionals are working together to stay vigilant and make the best treatment decisions for their patients by pooling their data with tools like the COVID-19 and Cancer Consortium, says Dr. Toni K. Choueiri.

Age and Gender Could Factor into Advanced Renal Cell Carcinoma Outcomes

September 1st 2020, 9:00pm

Video

Many factors impact outcomes in patients with advanced renal cell carcinoma, but recent findings suggest a patient’s age and gender are perhaps more important than previously realized.

FDA Approves First Comprehensive Genomic Profiling Liquid Biopsy Test for All Solid Cancers

August 10th 2020, 5:46pm

Article

The liquid biopsy test was also approved as a companion diagnostic test to uncover EGFR mutations in patients with NSCLC who could benefit from treatment with Tagrisso.

An Expert Looks to the Future of Metastatic Kidney Cancer Treatment

August 10th 2020, 5:00pm

Video

Dr. Toni K. Choueiri discusses what therapies are currently available for patients with metastatic renal cell carcinoma, as well as what new treatments could be on the horizon.

FDA Grants Breakthrough Therapy Designation to Novel Therapy for von Hippel-Lindau Disease-Associated RCC

August 7th 2020, 5:00pm

Article

The FDA based its decision on data from a phase 2 trial which showed that MK-6482 induced clinical responses among patients with von Hippel-Lindau disease-associated kidney cancer.

x